Q-omics provides the consensus-scored CCDC42 profile across patient tissues and cancer cell-line models. CCDC42 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, CCDC42 is differentially expressed in 8, with the highest sampling consensus in LUAD. Additionally, CCDC42 RNA expression shows 9,654 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight ACC, LUAD, and ESCA as cancer lineages where CCDC42 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CCDC42 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CCDC42 survival associations across molecular data types. CCDC42 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CCDC42 RNA expression–survival associations across cancer types. High CCDC42 expression shows unfavorable associations in ACC, MESO, LAML and LGG, but favorable associations in CESC and SKCM. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify ACC as the clearest survival context for CCDC42 RNA expression.
This table summarizes CCDC42 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for CCDC42. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CCDC42 shows lower tumor expression in LUAD, KICH, LUSC and LIHC and higher tumor expression in HNSC and KIRC. The LUAD box plot shows higher CCDC42 RNA expression in normal versus tumor tissue (log2 FC = −0.200, t-test p < 0.001).
This table shows molecular features associated with CCDC42 in patient tissues and cancer cell lines. In patient samples, CCDC42 shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set. In cancer cell lines, CCDC42 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and BLOOD_Leukemia.
